ArticleMedical molecular morphology2023

A novel pathologic marker, indoleamine 2,3-dioxygenase 1, for the cholangiopathy of immune checkpoint inhibitors-induced immune mediated hepatotoxicity as adverse events and the prediction of additional ursodeoxycholic acid treatment.

Kaori Yoshimura et al.PubMed ↗Publisher ↗

No numbers read from the abstract.